What does cervical cancer elimination mean?

The World Health Organization defines the elimination of cervical cancer as a public health problem as reducing the incidence rate to fewer than 4 cases per 100,000 women globally.

What are the WHO 90-70-90 targets?

The targets, to be achieved by 2030, are: 90% of girls fully vaccinated by age 15; 70% of women screened with a high-performance test by ages 35 and 45; and 90% of women identified with cervical disease receiving treatment.

When will cervical cancer be eliminated?

The timeline varies wildly by region. Countries like Australia may achieve elimination by 2028, while low-income nations may not reach the target until late in the 21st century without massive intervention.

Cervical Cancer Elimination Timeline

Tracking Progress Toward the WHO 90-70-90 Targets

For the first time in human history, the world has the tools and the coordinated strategy to eliminate a specific cancer. In November 2020, the World Health Organization (WHO) officially launched the Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. This initiative provides a clear framework and measurable milestones to guide global HPV vaccine access, screening, and treatment efforts.

Defining "Elimination"

In public health terminology, "elimination" does not mean the absolute eradication of every single case globally (which is currently only true for smallpox). Instead, the WHO defines the elimination of cervical cancer as reducing the annual incidence to fewer than 4 cases per 100,000 women-years in every country. Below this threshold, the disease is no longer considered a major public health burden.

The 2030 Interim Milestones: The 90-70-90 Targets

To put all countries on the path to elimination, the WHO established three interdependent pillars with specific targets to be met by the year 2030. These are widely known as the 90-70-90 targets:

90% Vaccination: 90% of girls fully vaccinated with the HPV vaccine by the age of 15.
70% Screening: 70% of women screened with a high-performance test (such as an HPV DNA test) by age 35, and again by age 45.
90% Treatment: 90% of women identified with cervical disease receiving appropriate treatment (90% of those with precancer treated, and 90% of those with invasive cancer managed).

Why these three pillars?

Vaccination is the primary preventative mechanism, aiming to stop infections before they occur. However, because the vaccine is prophylactic, it does not help women who are already infected. Therefore, robust screening is required to catch existing high-risk infections before they progress to cancer (secondary prevention), and accessible treatment (tertiary prevention, such as a LEEP procedure) is essential to manage precancers and existing malignancies. All three pillars must advance simultaneously to achieve elimination.

The Timeline: A Tale of Two Realities

The projected timeline for actual elimination (reaching the sub-4/100,000 threshold) is not uniform. It represents a stark dichotomy between high-income countries (HICs) and low- and middle-income countries (LMICs).

The Fast Track: High-Income Countries

Several HICs that implemented national vaccination programs early are already nearing the finish line. Australia, having combined a high-coverage school-based vaccination program with an advanced primary HPV DNA screening program, is widely projected to be the first nation to achieve elimination, potentially as early as 2028. The United Kingdom and the United States, despite slightly different implementation models, are also on track to reach elimination within the next two decades, provided they maintain or improve current coverage rates.

The Long Haul: LMICs and High-Burden Regions

Conversely, the timeline is drastically extended for regions bearing the highest disease burden, particularly in Africa and parts of Asia. In these areas, the lack of historical screening infrastructure and delayed access to the HPV vaccine mean that cervical cancer rates remain exceptionally high.

Epidemiological modeling indicates that even if the 90-70-90 targets are achieved globally by 2030, it will take several decades for the impact to fully manifest as elimination in the highest-burden countries. Without massive intervention and sustained international support (such as from Gavi), many low-income nations may not reach the elimination threshold until late in the 21st century.

Accelerating the Timeline

Recognizing the urgency, the global health community is deploying several critical strategies to compress this timeline and accelerate progress in LMICs.

The Single-Dose Schedule: The WHO's endorsement of the single-dose HPV vaccine regimen is the most significant recent accelerator. By halving costs and simplifying logistics, it allows nations to rapidly scale up vaccination coverage.
Self-Sampling for Screening: Moving away from traditional, resource-intensive Pap smears toward HPV DNA testing, specifically utilizing self-collected vaginal swabs, dramatically expands screening access to remote and under-screened populations.
Catch-up Campaigns: While the primary target is young girls, targeted HPV vaccine catch-up campaigns for older cohorts can expedite the decline in population-level viral prevalence.
Domestic Manufacturing: The rise of domestic vaccine production in countries like China and India is crucial for stabilizing supply and lowering costs globally.

Conclusion

The WHO's timeline for cervical cancer elimination is an ambitious but scientifically achievable goal. It requires unprecedented global cooperation, sustained funding, and the rapid adoption of innovative delivery models. While disparities in progress currently exist, the concerted push to hit the 2030 interim targets offers the promise of averting tens of millions of cancer cases and securing a future where cervical cancer is a disease of the past.